The pharmaceutical sector is on the brink of a radical transformation, catalyzed by the integration of artificial intelligence (AI) into its processes. This evolution is particularly evident in the initiatives of large companies such as AstraZeneca, which are investing heavily in AI to optimize the research and development (R&D) of new drugs. However, this technological advancement is not without challenges, notably for SMEs that must navigate an increasingly technological and competitive environment. The risks include technological dependency and increasing regulatory requirements.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
